Serum uric acid in patients with ST-segment elevation myocardial infarction: An innocent bystander or leading actor?

Nutr Metab Cardiovasc Dis. 2022 Jul;32(7):1583-1589. doi: 10.1016/j.numecd.2022.03.023. Epub 2022 Apr 4.

Abstract

Elevated serum uric acid (SUA) levels have been associated with several cardiovascular risk factors and the progression of coronary artery disease. In the setting of acute myocardial infarction, increasing evidence suggests that high SUA levels could be related to adverse outcomes. Interestingly elevated SUA levels have been linked to endothelial dysfunction, inflammation and oxidative stress. The aim of this review is to discuss the potential negative effects of SUA in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, analyzing the possible underlying pathophysiological mechanisms.

Keywords: Contrast-associated acute kidney injury; Myocardial infarct size; ST-Segment myocardial infarction; Serum uric acid.

Publication types

  • Review

MeSH terms

  • Humans
  • Myocardial Infarction* / diagnosis
  • Myocardial Infarction* / etiology
  • Myocardial Infarction* / therapy
  • Percutaneous Coronary Intervention* / adverse effects
  • ST Elevation Myocardial Infarction* / diagnosis
  • ST Elevation Myocardial Infarction* / therapy
  • Treatment Outcome
  • Uric Acid

Substances

  • Uric Acid